Register
Alirocumab reduces cardiac events after acute coronary syndrome |
Journal Updates
eMediNexus Coverage from: 
Alirocumab reduces cardiac events after acute coronary syndrome
eMediNexus,  13 March 2018
remove_red_eye 729 Views
#Cardiology #Internal Medicine #Pharmacist

1 Read Comments                

The proprotein convertase subtilisin-kexin 9 (PCSK9) inhibitor alirocumab was shown to reduce the rates of major adverse cardiovascular events (MACE) by 15% compared with placebo in patients with persistently high cholesterol despite high-intensity statin therapy, according to a study presented March 10, 2018 at the American College of Cardiologys 67th Annual Scientific Session in Orlando, Florida.

To continue reading this article
Or

Continue reading your article with a Emedinexus account..
Free Membership!